• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

    12/5/25 7:45:00 AM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MURA alert in real time by email

    WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the "Scheme") pursuant to which XRA 5 Corp. ("Sub"), a wholly-owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty") will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025 (the "Effective Date").

    Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon as practicable following the Effective Date, with DTC participant accounts expected to be credited and the distribution of cheques expected to be complete as soon as practicable. In accordance with the requirements of the Irish Takeover Rules, all consideration paid by Sub to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 19 December 2025.

    Cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market occurred with effect from 8.00 pm (U.S. Eastern Time) on 4 December 2025.

    Except as otherwise defined herein, capitalised terms used but not defined in this announcement have the same meanings as given to them in the definitive proxy statement of Mural dated 23 September 2025 relating to the Acquisition, which also constitutes a scheme circular under Irish law.

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

    FOR IMMEDIATE RELEASE

    Enquiries

    Mural Oncology plc

    [email protected]

    Lucid Capital Markets, LLC (Financial Adviser to Mural)

    570 Lexington Ave, 40th Floor

    New York, NY 10022

    Cautionary Note Regarding Forward-Looking Statements

    Statements contained in this announcement regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Mural, XOMA Royalty or Sub. Forward-looking statements are intended to be identified by words such as "anticipate", "target", "expect", "estimate", "intend", "plan", "believe", "will", "may", "would", "could" or "should" or other words of similar meaning or the negative thereof. Forward-looking statements include but are not limited to statements regarding the expected timing of the payment of the consideration paid by Sub to Scheme Shareholders and the expected timing of the cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market.

    These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements. Risks and uncertainties that may cause actual results to differ from expectations include: risks and uncertainties pertaining to Mural's business, including those described in Mural's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") and definitive proxy statement filed with the SEC on 23 September 2025, as well as Mural's subsequent filings with the SEC; and other potential risks and uncertainties related to XOMA Royalty, including those described in more detail in XOMA Royalty's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and its other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All subsequent oral or written forward-looking statements attributable to Mural, XOMA Royalty or Sub or any persons acting on their behalf are expressly qualified in their entirety by the cautionary statement above. None of Mural, XOMA Royalty or Sub undertake any obligation to update or revise the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.

    Statements Required by the Irish Takeover Rules 

    The directors of Mural accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Mural (who have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

    Lucid, which is authorized and regulated by the SEC and the Financial Industry Regulatory Authority ("FINRA") in the United States, is acting as financial adviser exclusively for Mural and for no one else in connection with the subject matter of this Announcement and will not regard any other person as its client in relation to the matters in this Announcement and will not be responsible to anyone other than Mural for providing the protections afforded to clients of Lucid or its affiliates, nor for providing advice in relation to any matter referred to in this Announcement. Neither Lucid nor any of its subsidiaries, affiliates or branches owes or accepts any duty, liability or responsibility whatsoever (whether direct, indirect, consequential, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Lucid in relation to the matters in this Announcement, any statement or other matter or arrangement referred to herein or otherwise.

    Davy Corporate Finance, which is authorized and regulated in Ireland by the Central Bank of Ireland, is acting exclusively for XOMA Royalty and no one else in connection with the matters referred to in this Announcement and will not be responsible to anyone other than XOMA Royalty for providing the protections afforded to clients of Davy Corporate Finance or for providing advice in connection with the matters referred to in this Announcement.

    Wilmer Cutler Pickering Hale and Dorr LLP and Arthur Cox LLP are acting as legal advisers on U.S. and Irish law matters respectively to Mural, and Gibson, Dunn & Crutcher LLP and Mason Hayes & Curran LLP are acting as legal advisers on U.S. and Irish law matters respectively to XOMA Royalty and Sub.

    General

    The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this announcement and all other documents relating to the Acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such restricted jurisdictions. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, each of Mural, XOMA Royalty and Sub disclaims any responsibility or liability for the violations of any such restrictions by any person.

    Publication on a Website

    In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this announcement will be available on Mural's website at https://ir.muraloncology.com/ by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication of this announcement. Neither the content of the website referred to in this announcement nor the content of any other websites accessible from hyperlinks on such website is incorporated into, or forms part of, this announcement.



    Primary Logo

    Get the next $MURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MURA
    $XOMA

    CompanyDatePrice TargetRatingAnalyst
    XOMA Royalty Corporation
    $XOMA
    4/17/2025$35.00Buy
    The Benchmark Company
    Mural Oncology plc
    $MURA
    3/25/2025Overweight → Equal-Weight
    Morgan Stanley
    Mural Oncology plc
    $MURA
    3/25/2025$18.00Strong Buy → Outperform
    Raymond James
    Mural Oncology plc
    $MURA
    6/28/2024$15.00Buy
    Rodman & Renshaw
    XOMA Royalty Corporation
    $XOMA
    4/29/2024$40.00Outperform
    Leerink Partners
    Mural Oncology plc
    $MURA
    4/4/2024$13.00Overweight
    Morgan Stanley
    XOMA Royalty Corporation
    $XOMA
    10/8/2021$56.00 → $69.00Buy
    HC Wainwright & Co.
    XOMA Royalty Corporation
    $XOMA
    9/9/2021$60.00 → $56.00Buy
    Aegis Capital
    More analyst ratings

    $MURA
    $XOMA
    SEC Filings

    View All

    SEC Form EFFECT filed by Mural Oncology plc

    EFFECT - Mural Oncology plc (0001971543) (Filer)

    12/9/25 12:15:09 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Mural Oncology plc

    S-8 POS - Mural Oncology plc (0001971543) (Filer)

    12/5/25 4:35:34 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Mural Oncology plc

    S-8 POS - Mural Oncology plc (0001971543) (Filer)

    12/5/25 4:34:14 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hughes Owen bought $2,505,000 worth of Depositary Shares - 8.375% B Cumulative Stock (100,000 units at $25.05), increasing direct ownership by 5,000% to 102,000 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    12/8/25 4:30:18 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Sitko Bradley bought $50,780 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $25.39), increasing direct ownership by 40% to 7,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    7/2/25 4:30:26 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    4/9/25 4:44:30 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hughes Owen bought $2,505,000 worth of Depositary Shares - 8.375% B Cumulative Stock (100,000 units at $25.05), increasing direct ownership by 5,000% to 102,000 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    12/8/25 4:30:18 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hickey Benjamin

    4 - Mural Oncology plc (0001971543) (Issuer)

    12/5/25 9:16:59 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Loew Caroline returned 293,059 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Mural Oncology plc (0001971543) (Issuer)

    12/5/25 9:10:35 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

    EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc ("Mural") (NASDAQ:MURA) (the "Acquisition") pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme"). Mural shareholders received $2.035 in cash per share (the "Consideration"). The Acquisition was approved by Mural shareholders at a special meeting of shareholders convened pursuant to section 450(1) of the Ir

    12/5/25 9:00:00 AM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

    WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the "Scheme") pursuant to which XRA 5 Corp. ("Sub"), a wholly-owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty") will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025 (the "Effective Date"). Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon

    12/5/25 7:45:00 AM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Announces Sanction of the Scheme by the High Court

    WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the "Scheme") pursuant to which XRA 5 Corp. ("Sub"), a wholly-owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"), will acquire the entire issued and to be issued share capital of Mural (the "Acquisition"). The Scheme and the Acquisition will become effective on delivery of the Court Order to the Irish Registrar of Companies. Delivery of the Court Order to the Irish Registrar of Companies

    12/3/25 4:30:00 PM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

    The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

    4/17/25 8:34:06 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology downgraded by Morgan Stanley

    Morgan Stanley downgraded Mural Oncology from Overweight to Equal-Weight

    3/25/25 12:58:54 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology downgraded by Raymond James with a new price target

    Raymond James downgraded Mural Oncology from Strong Buy to Outperform and set a new price target of $18.00

    3/25/25 11:43:59 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Financials

    Live finance-specific insights

    View All

    Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION  WALTHAM, Mass. and DUBLIN, Ireland, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA) ("Mural") today announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp. ("Sub"), a wholly owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"). As described in more detail below, a majority in number of the shareholders of record present and voting, either in person or by proxy and more than 99 perc

    10/24/25 4:25:31 PM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

    - Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Penn., Oct. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced that they have reached an agreement to amend their previously announced definitive share purchase agreement (the "Purchase Agreement," and such amendment, the "Amendment").   Under the Amendment, LAVA shareholders who tender their shares will now receive (i) an initial cash amount per share of $1.04 (the "

    10/17/25 11:45:00 AM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

    EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced the extension of the expiration of the tender offer to purchase all outstanding shares of common shares of LAVA, for (i) a cash amount to be determined in accordance with the Purchase Agreement, plus (ii) a non-transferable contingent value right ("CVR") per share representing the right to receive 75% of the net proceeds related to LAVA's two partnered assets and 75% of any net proceeds from any out license or sale of LAVA's unpartnered programs (the "Offer"). The Offer,

    10/2/25 4:43:26 PM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Leadership Updates

    Live Leadership Updates

    View All

    Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

    Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural's IL-18 program planned for Q4 2025 Mural reiterates guidance on projected cash runway into Q4 2025 WALTHAM, Mass. and DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of can

    11/13/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress

    Key data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management team to provide additional information not previously disclosed related to nemvaleukin study design, statistical assumptions, and study execution Clinicians to discuss treatment landscape of platinum-resistant ovarian cancer and mucosal melanoma, two indications with limited treatment options and poor outcomes for patients IND submission for Mural's IL-18 program planned for Q4 2025 WALTHAM, Mass and DUBLIN, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MUR

    9/26/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi

    WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee. "With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate mileston

    9/23/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/14/24 5:15:53 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/12/24 3:52:44 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/4/24 2:39:13 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care